促红细胞生成素在治疗恶性血液病贫血中应用  

Application of Erythropoietin in Management of Anemia in Malignancy Hematologic Disease

作　　者：赵恒[1] 邬国和[1] 李东宁[1] 颜丽华[1] 刘定胜[1] 李萍[1] 

机构地区：[1]南昌大学第三附属医院血液科,江西南昌330008

出　　处：《实用临床医学（江西）》2006年第5期26-27,30,共3页Practical Clinical Medicine

摘　　要：目的:探讨促红细胞生成素(EPO)在治疗恶性血液病患者贫血中的临床应用。方法:随机将36例恶性血液病伴有贫血患者分为2组各18例进行对照研究,治疗组18例给予益比奥1万单位皮下注射,每周3次。对照组不用EPO,其他同治疗组。结果:治疗组18例患者治疗前后血红蛋白(Hb)、红细胞压积(HCT)分别为(65.7±9.8)g/L,(0.21±0.03)和(101.2±15.3)g/L,(0.32±0.02)。治疗组治疗4周后Hb浓度较对照组(72.1±12.5)g/L上升明显,P<0.01。结论:应用EPO治疗恶性血液病贫血,不仅能提高Hb水平,而且可以减少输血,副反应少,值得应用于临床。Objective： To approach clinical application of erythropoietin in management of anemia in malignancy hematologic disease. Methods：Thirty-slx cases of anemia of malignancy hematologic disease were randomly divided into two groups with 18 in each group. In treatment group Yibio was administrated at 10 000 u by subcutaneous injection three times a week; but in control group Yibio was not. Results. In treatment group the Hb and HCT before and after treatment were 65.7±9.8g/L , 0.21±0.03 and 101.2±15.3 g/L,0.32±0.02,respectively. The HBin treat- ment group after 4 weeks treatment with Yibio was significant higher than that in control group 72.1±12.5g/L , （P〈0.01）. Conclusion： Application of erythropoietin in management of anemia of malignancy hematologic disease not only elevated the Hb level, but also diminished blood transfusion. The side effects were little. Yibio is worth to be used.

关 键 词：贫血 促红细胞生成素 血红蛋白 

分 类 号：R556[医药卫生—血液循环系统疾病]